Collectively, these findings improve our understanding of how exactly KRAS mutant cancer cells upregulate expression of AATs as upstream stimulants, which is clinically relevant, since they are overexpressed in multiple cancers and therefore represent attractive therapeutic targets. This evidence concerns the gene KRAS and cancer.